C
Clara Lemos
Researcher at Bayer
Publications - 38
Citations - 1576
Clara Lemos is an academic researcher from Bayer. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 20, co-authored 36 publications receiving 1412 citations. Previous affiliations of Clara Lemos include Max Delbrück Center for Molecular Medicine & University of Porto.
Papers
More filters
Journal ArticleDOI
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans,Niels E. Franke,Yehuda G. Assaraf,Jacqueline Cloos,Ina van Zantwijk,Celia R. Berkers,George L. Scheffer,Kabir Debipersad,Katharina Vojtekova,Clara Lemos,Joost W. van der Heijden,Bauke Ylstra,Godefridus J. Peters,Gertjan L. Kaspers,Ben A. C. Dijkmans,Rik J. Scheper,Gerrit Jansen +16 more
TL;DR: A novel mechanism of bortezomib resistance associated with the selective overexpression of a mutant PSMB5 protein is established and is established in human myelomonocytic THP1 cells by exposure to stepwise increasing concentrations of bortsomib.
Journal ArticleDOI
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
Elisa Giovannetti,Clara Lemos,Christina Tekle,Kees Smid,Sara Nannizzi,Jose A. Rodriguez,S. Ricciardi,Romano Danesi,Giuseppe Giaccone,Godefridus J. Peters +9 more
TL;DR: Erlotinib and pemetrexed showed a strong synergism in NSCLC cells, regardless of their genetic characteristics, and these mechanisms support the clinical investigation of these markers.
Journal ArticleDOI
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells
Ulrike Sack,Wolfgang Walther,Dominic A. Scudiero,Mike Selby,Jutta Aumann,Clara Lemos,Iduna Fichtner,Peter M. Schlag,Peter M. Schlag,Robert H. Shoemaker,Ulrike Stein +10 more
TL;DR: Calcimycin restricts Wnt/β-catenin–regulated S 100A4 expression, leading to reduced S100A4-mediated cell migration and invasion in colon cancer cells, as well as to inhibition of metastasis formation in xenografted mice.
Journal ArticleDOI
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
TL;DR: The role of one selected ABC-transporter family member, the breast cancer resistance protein (BCRP/ABCG2), in the (pre)clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors is discussed.
Journal ArticleDOI
Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.
TL;DR: This article envisages the various drugs being developed for treating MDR in cancer cells and especially the acridone derivatives which are being developed by the author.